BNP Paribas Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$153K Buy
627
+2
+0.3% +$434 ﹤0.01% 1446
2026
Q1
$106K Buy
625
+157
+34% +$27.1K ﹤0.01% 1494
2025
Q4
$85K Buy
468
+142
+44% +$19.8K ﹤0.01% 1516
2025
Q3
$40K Hold
326
– – ﹤0.01% 1123
2025
Q2
$34K Buy
+326
New +$34.5K ﹤0.01% 1280

Other funds holding AXSM

BNP Paribas Asset Management's AXSM Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Axsome Therapeutics (AXSM) stake by 0.32% in Q2 2026, buying an estimated $434 and bringing the position to 627 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

BNP Paribas Asset Management first reported a position in AXSM in Q2 2025 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • BNP Paribas Asset Management held 627 shares of Axsome Therapeutics worth $153K as of Q2 2026.
  • BNP Paribas Asset Management bought 2 Axsome Therapeutics shares in Q2 2026, an estimated $434.
  • Axsome Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1446 holding.
  • BNP Paribas Asset Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.